Company
Every investor coverage indicates participated in a round CUREator+ Dementia and Cognitive Decline raised.
Companies CUREator+ Dementia and Cognitive Decline acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming CUREator+ Dementia and Cognitive Decline. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Seven Australian startups were selected in Round 2 of the CUREator+ Dementia & Cognitive Decline program to share $15.6 million for developing dementia therapies, diagnostics and technologies; none are named in the visible text.
Denteric has begun recruiting early Alzheimer's patients for a Phase I trial of its gingipain-targeting therapy GPV381, with funding from the CUREator+ Dementia program and the Medical Research Future Fund.